Filgrastim biosimilar (Sandoz)

非格司亭（山德士）

Report date: 2026/05/23 20:00:57

Base Information

Drug NameFilgrastim biosimilar (Sandoz)
Drug Alias Name非拉司亭（山德士）Filgrastimum (Sandoz)Filgrastim BS (Sandoz)Filgrastim Hexal - SandozFilgrastim-sndz +[8] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionColony stimulating factor 3 receptor agonists
TargetsColony stimulating factor 3 receptor
Therapy Area/IndicationsChemotherapy-Induced Febrile NeutropeniaFebrile NeutropeniaNeutropenia
Global Approved IndicationsChemotherapy-Induced Febrile NeutropeniaFebrile NeutropeniaNeutropenia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2009/02/06
Country/TerritoryCzechiaUnited StatesUkraine +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSandoz
China Registration ClassN/A

Develop Information

Active CompaniesHexal AgClariant Produkte (Schweiz) AgSandoz Inc +[4] 
Inactive CompaniesSandoz
Active IndicationsChemotherapy-Induced Febrile NeutropeniaFebrile NeutropeniaNeutropenia
Inactive IndicationsN/A

Other Information

ATC CodeL03AA02
Related LinksN/A